// App-Quantinova.ai

199 : Izokibep, a Novel IL-17A Inhibitor, Improves Patient-reported Outcomes – 16-Week Results from a Placebo-controlled Phase 2 Study in Patients with Active Psoriatic Arthritis

Researchers

Presenter

  • Peter Taylor

Principal Investigators

  • Frank Behrens

  • Philip J Mease

  • Dieter Wetzel

  • Paul Peloso

  • Nicolai Brun

  • Brian Wiens

  • Jan Brandt-Juergens

  • Edit Drescher

  • Eva Dokoupilova

  • Anna Rowińska-Osuch

  • Nadia Abdel- Kader Martin

  • Kurt de Vlam

Medical Centers

  • Medical Plus, s.r.o. & Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Brno, Prague, Czech Republic

  • Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

  • Affibody AB, Solna, Sweden

  • ETG Network - Rheumatology, Warsaw, Poland

  • Hospital Infanta Luisa Quiron, Rheumatology, Sevilla, Spain

  • Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany

  • Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany

  • University of Oxford, Oxford, United Kingdom

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Veszprem Megyei Csolnoky Ferenc Korhaz, Budapest, Hungary

  • ACELYRIN, Naples, FL

Locations

  • United Kingdom

  • Germany

  • United States

  • Sweden

  • Hungary

  • Czech Republic

  • Poland

  • Spain

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • Interleukin 17A

  • Tumor necrosis factor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Prospective

  • Controlled

Phase

  • II

Study Id's

  • NCT04713072

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved